Satsuma Pharmaceuticals (STSA) Stock Forecast, Price & News

Satsuma Pharmaceuticals (NASDAQ:STSA) Frequently Asked Questions

Is Satsuma Pharmaceuticals a buy right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Satsuma Pharmaceuticals in the last twelve months. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Satsuma Pharmaceuticals stock.
View analyst ratings for Satsuma Pharmaceuticals or view top-rated stocks.

Are investors shorting Satsuma Pharmaceuticals?

Satsuma Pharmaceuticals saw a drop in short interest in May. As of May 15th, there was short interest totaling 381,200 shares, a drop of 27.9% from the April 30th total of 529,000 shares. Based on an average trading volume of 64,000 shares, the short-interest ratio is presently 6.0 days. Approximately 1.7% of the shares of the stock are sold short.
View Satsuma Pharmaceuticals' Short Interest.

When is Satsuma Pharmaceuticals' next earnings date?

Satsuma Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, August 9th 2022.
View our earnings forecast for Satsuma Pharmaceuticals.

How were Satsuma Pharmaceuticals' earnings last quarter?

Satsuma Pharmaceuticals, Inc. (NASDAQ:STSA) announced its earnings results on Tuesday, May, 10th. The financial services provider reported ($0.49) earnings per share for the quarter, missing the consensus estimate of ($0.48) by $0.01.
View Satsuma Pharmaceuticals' earnings history.

What price target have analysts set for STSA?

3 brokerages have issued twelve-month price targets for Satsuma Pharmaceuticals' stock. Their forecasts range from $5.00 to $15.00. On average, they anticipate Satsuma Pharmaceuticals' stock price to reach $11.00 in the next twelve months. This suggests a possible upside of 221.6% from the stock's current price.
View analysts' price targets for Satsuma Pharmaceuticals or view top-rated stocks among Wall Street analysts.

Who are Satsuma Pharmaceuticals' key executives?

Satsuma Pharmaceuticals' management team includes the following people:

• Mr. John A. Kollins MBA, Pres, CEO & Director (Age 59, Pay $830k)
• Mr. Thomas P. O'Neil, Chief Financial Officer (Age 57, Pay $550.08k)
• Dr. Detlef F. Albrecht, Chief Medical Officer (Age 61, Pay $625.97k)
• Mr. Mic Iwashima, VP & Head of Operations (Age 44)
• Mr. Robert Schultz, VP & Head of CMC (Age 57)
• Dr. Shannon Strom Ph.D., VP & Head of Regulatory Affairs (Age 46)
• Mr. Robert M. Janosky, Chief Commercial Officer

Who are some of Satsuma Pharmaceuticals' key competitors?

Some companies that are related to Satsuma Pharmaceuticals include The PNC Financial Services Group (PNC), Truist Financial (TFC), M&T Bank (MTB), SVB Financial Group (SIVB), First Republic Bank (FRC), Fifth Third Bancorp (FITB), Regions Financial (RF), Huntington Bancshares (HBAN), KeyCorp (KEY), Signature Bank (SBNY), First Horizon (FHN), First Citizens BancShares (FCNCA), East West Bancorp (EWBC), Western Alliance Bancorporation (WAL) and Webster Financial (WBS).
View all of STSA's competitors.

What other stocks do shareholders of Satsuma Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Satsuma Pharmaceuticals investors own include Verrica Pharmaceuticals (VRCA), AbbVie (ABBV), Adaptimmune Therapeutics (ADAP), Alector (ALEC), Dynavax Technologies (DVAX), Homology Medicines (FIXX), Gilead Sciences (GILD), Novan (NOVN), Pfizer (PFE) and Akebia Therapeutics (AKBA).

When did Satsuma Pharmaceuticals IPO?

(STSA) raised $75 million in an initial public offering on Friday, September 13th 2019. The company issued 5,000,000 shares at $14.00-$16.00 per share. Credit Suisse, SVB Leerink and Evercore acted as the underwriters for the IPO.

What is Satsuma Pharmaceuticals' stock symbol?

Satsuma Pharmaceuticals trades on the NASDAQ under the ticker symbol "STSA."

Who are Satsuma Pharmaceuticals' major shareholders?

Satsuma Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (2.05%), Ghost Tree Capital LLC (1.50%), Walleye Capital LLC (0.83%), Walleye Capital LLC (0.83%), Dimensional Fund Advisors LP (0.70%) and BlackRock Inc. (0.43%). Company insiders that own Satsuma Pharmaceuticals stock include Commodore Capital Lp, Detlef Albrecht and Thomas P O'neil.
View institutional ownership trends for Satsuma Pharmaceuticals.

Which institutional investors are selling Satsuma Pharmaceuticals stock?

STSA stock was sold by a variety of institutional investors in the last quarter, including Ghost Tree Capital LLC, BlackRock Inc., Vanguard Group Inc., and Simplex Trading LLC.
View insider buying and selling activity for Satsuma Pharmaceuticals or view top insider-selling stocks.

Which institutional investors are buying Satsuma Pharmaceuticals stock?

STSA stock was bought by a variety of institutional investors in the last quarter, including Walleye Capital LLC, Walleye Capital LLC, Dimensional Fund Advisors LP, and State Street Corp.
View insider buying and selling activity for Satsuma Pharmaceuticals or or view top insider-buying stocks.

How do I buy shares of Satsuma Pharmaceuticals?

Shares of STSA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Satsuma Pharmaceuticals' stock price today?

One share of STSA stock can currently be purchased for approximately $3.42.

How much money does Satsuma Pharmaceuticals make?

Satsuma Pharmaceuticals has a market capitalization of $107.89 million. The financial services provider earns $-51.17 million in net income (profit) each year or ($1.78) on an earnings per share basis.

How many employees does Satsuma Pharmaceuticals have?

Satsuma Pharmaceuticals employs 21 workers across the globe.

When was Satsuma Pharmaceuticals founded?

Satsuma Pharmaceuticals was founded in 2016.

What is Satsuma Pharmaceuticals' official website?

The official website for Satsuma Pharmaceuticals is www.satsumarx.com.

How can I contact Satsuma Pharmaceuticals?

Satsuma Pharmaceuticals' mailing address is 400 OYSTER POINT BOULEVARD SUITE 221, SOUTH SAN FRANCISCO CA, 64080. The financial services provider can be reached via phone at 650-410-3200.